Botanix Pharmaceuticals sees revenue surge 857% after Sofdra launch

Botanix Pharmaceuticals reported a substantial increase in revenues from customer sales, rising to $5,757,266 for the year ended June 30, 2025, from $601,820 in the prior year, an 857% increase. This growth was primarily driven by the successful launch and commercialization of Sofdra topical gel in February 2025, which generated gross sales of approximately $25,279,000 during its first six months.

Despite the strong revenue growth, the company reported a comprehensive loss after tax of $86,396,186 for the year, an increase from $13,869,709 in 2024. This expanded loss is attributed to increased operating costs, including manufacturing Sofdra inventory, scaling company infrastructure, and ramping up marketing efforts for the product launch. The company's cash balance stood at $64,966,581 as of June 30, 2025.

In preparation for future growth, Botanix expanded its sales force, adding 27 sales professionals in January 2025 and an additional six fully trained professionals in Q1 FY2026, with 17 more planned for October 2025. The company’s fulfillment platform demonstrated positive trends, with 16,869 prescriptions filled during the six-month period post-launch.